MON-531 Prevalence and Risk Factors of Hypercortisolism Among Overweight or Obese Filipinos with Type 2 Diabetes Mellitus

Abstract Disclosure: K.B. de la Cerna: None. O.C. Dampil: None. F.T. Bautista: None. Background: Occult hypercortisolism may be present in a subset of patients with type 2 diabetes mellitus (T2DM). This maybe present in 2-9% of patients with T2DM, rising to as much as 20% in recent studies. The prevalence might even be higher among those with signs consistent with hypercortisolism such as obesity. Despite its clinical relevance, the prevalence of hypercortisolism in Filipino patients with T2DM remain unexplored. This study aimed to determine the prevalence of hypercortisolism and identify associated risk factors among overweight or obese Filipino patients with T2DM. Methods: A single-center, cross-sectional study was conducted in a tertiary hospital from September to December 2024. We examined 159 overweight or obese Filipino patients aged 19-80 years with T2DM. Data on demographics, clinical characteristics, and comorbidities were collected. Hypercortisolism was screened using the low-dose dexamethasone suppression test (DST), with cortisol levels ≥1.8 μg/dL indicating a positive result. Risk factors were analyzed using univariate and multivariate logistic regression. Results: The prevalence of a non-suppressed low dose dexamethasone suppression test was 8.81% (95% CI: 4.90-14.33). Identified significant risk factors were metabolic dysfunction associated liver disease (MAFLD) (adjusted odds ratio [aOR]: 442.24; p = 0.009), low HDL levels (aOR: 0.94; p = 0.028) and elevated creatinine levels (aOR: 1.02; p = 0.049). Other factors such as sex, BMI, Hba1c and hypertension were not statistically significant. Conclusion: The prevalence of hypercortisolism is 8.81%, this is consistent with previous findings. MAFLD, low HDL levels, and elevated creatinine levels were significantly associated with a non-suppressed low-dose dexamethasone suppression test, indicating that these metabolic abnormalities may have a more substantial impact on the clinical and biochemical profile of this population. Presentation: Monday, July 14, 2025